7.3. follow-up: local treatment curative intent. 7.3.1. definition local treatment defined rp rt, either imrt plus igrt ldr- hdr-bt, combination these, including neoadjuvant adjuvant hormonal therapy. unestablished alternative treatments hifu, cryosurgery focal therapy options follow general principles presented section. general, confirmed rising psa considered sign disease recurrence. 7.3.2. follow-up? first post-treatment clinic visit focuses detecting treatment-related complications assist patients coping new situation apart providing information pathological analysis. men pca increased risk depression attention mental health status required . tumour patient characteristics may prompt changing follow-up schedule. follow-up also allows introduction additional / salvage treatments considered necessary light expected life-expectancy, patients symptoms eau risk categories biochemical recurrence (see 6.1 table 4.3) 7.3.3. follow-up? procedures indicated follow-up visits vary according clinical situation. disease-specific history mandatory every follow-up visit includes psychological aspects, signs disease progression, treatment-related complications. evaluation treatment-related complications post-treatment period highlighted sections 8.2. examinations used cancer-related follow-up curative surgery rt discussed below. 7.3.3.1.prostate-specific antigen monitoring measurement psa cornerstone follow-up local treatment. psa thresholds depend local treatment used, psa recurrence almost always precedes clinical recurrence . key question establish psa rise clinically significant since psa increases clinical value (see section 6.4.2) . prospective studies available optimal timing psa testing impact oncological outcomes. 7.3.3.1.1. prostate-specific antigen monitoring radical prostatectomy following rp, psa level expected undetectable. biochemical recurrence rising psa prostatectomy defined section 6.3. prostate-specific antigen level expected undetectable two months rp . prostate-specific antigen generally determined every six months three years yearly thereafter evidence specific interval low mainly based observation early recurrences likely associated rapid progression . rising psa may occur longer intervals 20 years treatment depends initial risk group . yearly psa three years considered adequate considering fact longer interval bcr correlated lower eau-bcr risk score around 50% recurrence expected beyond three years, follow-up terminated life expectancy drops < 10 years. mentioned section 6.4.2 definitive threshold given relapse rp. persistently measurable psa patients treated rp discussed section 6.3.6. ultrasensitive psa assays remain controversial routine follow-up rp. men psa nadir < 0.01 ng/ml high (96%) likelihood remaining relapse-free within two years . addition, post-rp psa levels > 0.01 ng/ml combination clinical characteristics isup grade group surgical margin status may predict psa progression useful establish follow-up intervals . however, 86% men reported psa values 0.2 ng/ml five years initial psa nadir 0.1 ng/ml within six months surgery . 7.3.3.1.2. prostate-specific antigen monitoring radiotherapy following rt, psa drops slowly compared post rp. psa nadir < 0.5 ng/ml associated favourable outcome rt although optimal cut-off value remains controversial . interval reaching psa nadir three years, more. 2006 rtog-astro consensus conference phoenix definition radiation failure proposed establish better correlation definition clinical outcome (mainly metastases), namely, increase 2 ng/ml post-treatment psa nadir . definition also applies patients received adt . 7.3.3.2. digital rectal examination local recurrence curative treatment possible without concomitant rise psa level although rarely . proven patients unfavourable undifferentiated tumours. prostate specific antigen dre comprise useful combination first-line examination follow-up rt role dre questioned since failed detect local recurrence absence rising psa series 899 patients . series 1,118 prostatectomy patients, local histologically proven recurrence found dre alone psa measurement may efficient test needed rp . 7.3.3.3. transrectal ultrasound, bone scintigraphy, ct, mri pet/ct imaging techniques place routine follow-up localised pca long psa rising. imaging justified patients findings affect treatment decisions, either case bcr patients symptoms (see section 6.4.4.3 detailed discussion). 7.3.3.4. functional follow-up local treatments pca may cause short- long-term side effect various degree affect patients’ qol. quality control, order help patient choosing optimal treatment him, essential functional outcomes treatment given measured registered validated reproducable methods. order adress side effects impact qol specific tools ‘patient-reported outcome measures’ (proms) developed validated men pca. questionnaires assess common issues pca diagnosis treatment generate scores reflect impact perceptions hrqol. discussion see section 8.3. 7.3.4. long follow-up? patients fail treatment pca within seven years local therapy . patients followed closely initial post-treatment period risk failure highest. psa measurement, disease-specific history dre (if considered) recommended every six months three years annually. whether follow-up stopped psa remains undetectable (after rp) stable (after rt) remains unanswered question, seems fair follow-up done point recurrence found patient fit enough salvage therapy. risk assessment predict metastases-free pca-specific survival recurrence primary treatment may guide individual decisions need longer follow-up . even men psa-dt less ten months rp choose defer treatment, median mfs 192 months os 204 months rp observed, indicating relatively long disease-free intervals observed men rising psa local treatment . symptomatic recurrence without psa rise extremely rare, however, symptoms typical recurrent disease may vary poorly defined published data. case following symptoms psa testing performed exclude possible cancer recurrence particular men followed regular testing psa levels: pelvic/skeletal pain, haematuria, progressive luts, progressive lower body oedema, progressive bowel complaints complaints fatigue, sarcopenia unexplained weight loss . 7.3.5. summary evidence guidelines follow-up treatment curative intent summary evidencelea detectable psa, indicating relaps disease, must differentiated clinically meaningful relapse. psa threshold best predicts metastases rp > 0.4 ng/ml > nadir + 2 ng/ml imrt/vmat plus igrt (± adt).3 recommendationsstrength ratingroutinely follow-up asymptomatic patients obtaining least disease-specific history prostate-specific antigen measurement.strongat recurrence, perform imaging result affect treatment planning.strong